title: Application of Proteomic Techniques for Improved Stratification and Treatment of Schizophrenia Patients.
abstract: For major psychiatric disorders such as schizophrenia, there have been shortcomings in the translation of scientific findings into new treatments and this has led to diminished interest for large pharmaceutical companies. This chapter describes how incorporation of proteomic approaches into the clinical pipeline can lead to identification and implementation of biomarker tests for improved patient characterization, prediction of treatment response and monitoring treatment effects to help revitalize efforts in this important area. In addition, the construction of specific biomarker tests for disease prediction should smooth the progress of early intervention strategies which, in turn, may help to slow disease onset or progression. Finally, the development of purpose-built biomarker tests using lab-on-a-chip platforms with smartphone readouts will help to shift the diagnosis and treatment of this major psychiatric disorder into point-of-care settings for increased effectiveness and improved patient outcomes.
authors.affiliation: Department of Psychiatry, University of Magdeburg, Leipziger Strasse 44, 39120, Magdeburg, Germany. johann.steiner@med.ovgu.de.
authors.forename: Johann
authors.initials: J
authors.lastname: Steiner
authors.affiliation: Laboratory of Neuroproteomics, Department of Biochemistry and Tissue Biology, Institute of Biology, University of Campinas (UNICAMP), Rua Monteiro Lobato 255 F/01, Cidade Universitária Zeferino Vaz, 13083-862, Campinas, Brazil.
authors.forename: Paul C
authors.initials: PC
authors.lastname: Guest
authors.affiliation: Laboratory of Neuroproteomics, Department of Biochemistry and Tissue Biology, Institute of Biology, University of Campinas (UNICAMP), Rua Monteiro Lobato 255 F/01, Cidade Universitária Zeferino Vaz, 13083-862, Campinas, Brazil.|UNICAMP's Neurobiology Center, Rua Monteiro Lobato 255, Cidade Universitária Zeferino Vaz, 13083-862, Campinas, Brazil.
authors.forename: Daniel
authors.initials: D
authors.lastname: Martins-de-Souza
mesh_terms: D014150:Antipsychotic Agents / Q000494:pharmacology / Q000627:therapeutic use; D015415:Biomarkers / Q000097:blood*; D005544:Forecasting; D020022:Genetic Predisposition to Disease; D006728:Hormones / Q000097:blood; D006801:Humans; D007249:Inflammation / Q000097:blood; D038801:International Classification of Diseases; D056656:Lab-On-A-Chip Devices; D009490:Neurosecretory Systems / Q000187:drug effects / Q000503:physiopathology; D000067716:Point-of-Care Testing; D040901:Proteomics / Q000295:instrumentation / Q000379:methods* / Q000458:organization & administration; D012559:Schizophrenia / Q000097:blood / Q000145:classification / Q000175:diagnosis* / Q000628:therapy
chemical_list: D014150:Antipsychotic Agents; D015415:Biomarkers; D006728:Hormones
keywords: Biomarkers; Lab-on-a-chip; Mass spectrometry; Plasma multiplex immunoassay; Point-of-care; Proteomics; Schizophrenia; Serum; Smartphone apps